FindTrial
Sign In

Ingestion of Cannabis oil in Fibromyalgic people

Cannabis oil in Fibromyalgic people

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-2f8mtn
Enrollment
Unknown
Registered
2020-03-17
Start date
2019-09-27
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibromyalgia

Interventions

A randomized, double-blind, placebo-controlled clinical trial was conducted for eight weeks to determine the benefits of a THC-rich Cannabis oil on symptoms and quality of life of people with Fibromya
Drug
E02.190.755

Sponsors

Escola de Saúde Pública de Florianópolis
Lead Sponsor
Escola de Saúde Pública de Florianópolis
Collaborator

Eligibility

Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Fibromyalgia diagnosis (ACR 2010 criteria); age over 18 years; ability to sign the informed consent form; presence of moderate to severe symptoms despite therapies in use; at least one medical or nursing consultation at Health Center on the last year.

Exclusion criteria

Exclusion criteria: Decompensated organic comorbidities and/or risk psychiatric conditions (schizophrenia, psychosis, severe personality disorder, current suicidal ideation); other well defined cause of chronic pain; current pregnancy/lactation; moderate or severe cognitive impairment; history of cannabinoids sensitivity.

Design outcomes

Primary

MeasureTime frame
Significant improvement in symptoms and quality of life of patients in the Intervention Group, comparing the pre-intervention and post-intervention moments, assessed with the Fibromyalgia Impact Questionnaire—

Secondary

MeasureTime frame
Não são esperados desfechos secundários—

Countries

Brazil

Contacts

Public ContactCarolina Chaves

Escola de Saúde Pública de Florianópolis

chavescarol@hotmail.com55 51 991438525

Outcome results

None listed

Source: REBEC (via WHO ICTRP)